Resource TableImage 1Unique stem cell line identifierJCLRIi001-A-1Alternative name of stem cell lineiCas9-FL-BCP-hiPSCInstitutionJosep Carreras Leukemia Research InstituteContact information of distributorJulio Castaño, <jcastano@carrerasresearch.org>Type of cell lineiPSCOriginhumanAdditional origin infoAge: 19--22 weeks of human fetal development\
Sex: XXCell sourceFetal liver B-cell progenitorsMethod of reprogrammingNon-integrative (Sendai virus)Associated diseaseNon applicableGene/locusCas9 inserted in AAVS1 locusMethod of modificationCRISPR-Cas9Gene correctionNOName of transgene or resistanceCas9Inducible/constitutive systemDoxycycline inducible systemDate archived/stock dateDecember 2016Cell line repository/bankEthical approvalPatient\'s informed consent obtained.\
Institutional Review Board approval obtained (CMRB-CEIC-26/2013)

Resource utility {#s0005}
================

This iCas9-FL-BCP-iPSC constitutes a unique tool facilitating the screening on multiple sgRNAs (and libraries) for the generation of locus-specific genetic-edited (knock-in, knock-out, codon substitution, structural rearrangements, etc.) hiPSC for developmental biology, compound screening and disease modeling.

Resource details {#s0010}
================

Fresh fetal liver (FL) was collected from developing human embryos aborted at 19--22 weeks of pregnancy. Human tissue was provided by The Vrelinghuis abortion clinic (Utrecht, The Netherlands) upon signed informed consent and approval by our local Ethics and Biozahard Board Committees (CMRB-CEIC-26/2013) through a formal collaboration with the Erasmus-Medical Centre, Rotterdam, The Netherlands). Mononuclear cells (MNCs) were isolated using Ficoll-Hypaque and CD34 + CD19 + B-cell progenitors (BCP) were FACS-purified and reprogrammed by infection with non-integrative tetracistronic SeV vectors encoding the transcription factors OCT4, SOX2, KLF4, and MYC (OSKM) ([@bb0005], [@bb0010]). Resulting FL CD34 + CD19 + − iPSC lines (FL-BCP-hiPSC) were established as previously reported ([@bb0005], [@bb0010], [@bb0015]). This FL-BCP-hiPSC was genome-edited to harbor the Cas9 coding sequence controlled by a doxycycline-inducible cassette in the genomic "safe harbor" AAVS1 (iCas9-FL-BCP-hiPSC). A single cassette containing both the rTetR activator under CAG promoter and the Tetracycline Response Element (TRE) promoter driving the expression of Cas9, was inserted in the AAVS1 locus by homologous recombination using the Cas9 nuclease and a guide RNA (gRNA) sequence ([@bb0020]) against intron 1 of AAVS1 locus ([Fig. 1](#f0005){ref-type="fig"} panel A). The [Fig. 1](#f0005){ref-type="fig"} panel A shows a schematic representation of the donor vector used for insertion of the iCas9 cassette into the AAVS1 locus (HA, homology arm; puro, puromycin; SA, splice acceptor; T2A, self-cleaving 2A peptide; CAG, CMV early enhancer/chicken β actin promoter. rTetR, reverse Tet repressor; pA, poly A signal; TRE, Tet response element). Correct genomic integration of a unique copy of Cas9 was confirmed by both genomic PCR (not shown) and Southern blot analysis ([Fig. 1](#f0005){ref-type="fig"} panel B) in several iPSC clones, using a 5′-internal probe (left panel) and a 3′-external probe (right panel). Red asterisks indicate clones with the desired targeted insertions of the iCas9. Three iCas9-FL-BCP-hiPSC clones were induced for 72 h with 2 μg/ml of doxycycline and analyzed for Cas9 expression by qPCR ([Fig. 1](#f0005){ref-type="fig"} panel C), showing a robust, non-leaky expression of Cas9. To functionally validate the Cas9 expression, iCas9-FL-BCP-hiPSCs were nucleofected with different gRNAs against three hematopoietic transcription factors (*MLL*, *GATA2* and *AF4*) in presence/absence of doxycycline. The T7 endonuclease I assay confirmed a high percentage (25%--62%) of cleavage ([Fig. 1](#f0005){ref-type="fig"} panel D). Red asterisks depict the expected T7EI-specific fragments used to quantify indel frequency. The in silico-predicted ([crispr.mit.edu](http://crispr.mit.edu){#ir0030}) top off-targets of AAVS1 gRNA (*RNF4*, *RHOT2*, *FAIM2*, *RPL8*, *BTNL8*, *MYBL2*) were sequence-verified in iCas9-FL-BCP-hiPSCs and they were consistently found unaltered, demonstrating the high specificity of the approach used (data not shown).Fig. 1CRISPR/Cas9-mediated generation of iCas9-FL-BCP-hiPSCs by gene targeting at the AAVS1 locus.Fig. 1

Importantly, iPSCs remained pluripotent after CRISPR/Cas9 gene editing. iCas9-FL-BCP-hiPSCs retained hESC-like morphology and expressed the pluripotency markers alkaline phosphatase (AP) ([Fig. 1](#f0005){ref-type="fig"} panel E), *OCT4*, *NANOG*, *SOX2*, *REX1*, *CRIPTO*, and *DNMT3B* ([Fig. 1](#f0005){ref-type="fig"} panel F). Endogenous expression of *NANOG* and *OCT4* was accompanied by the extensive loss of CpG methylation in their promoters ([Fig. 1](#f0005){ref-type="fig"} panel G). By flow cytometry, gene-edited iPSCs consistently expressed SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81 ([Fig. 1](#f0005){ref-type="fig"} panel H). In vivo, the differentiation capacity was confirmed by teratoma formation in NSG mice comprising tissue representing all three germ layers ([Fig. 1](#f0005){ref-type="fig"} panel I).

Materials and methods {#s0015}
=====================

iPSC generation, maintenance and characterization {#s0020}
-------------------------------------------------

iPSCs were generated using OKSM polycistronic SeV vector ([@bb0005], [@bb0010]) and were fully characterized before and after gene edition as previously described ([@bb0015]).

Promoter demethylation {#s0025}
----------------------

Bisulfite pyrosequencing of *OCT4* and *NANOG* promoters was done as described ([@bb0015]).

Immunophenotyping {#s0030}
-----------------

Antibodies used to check by flow cytometry the pluripotency-associated markers are detailed in [Table 2](#t0010){ref-type="table"}.

CRISPR/Cas9-edition of hiPSCs expressing a doxycycline-inducible Cas9 {#s0035}
---------------------------------------------------------------------

The CAG-rTetR cassette was PCR amplified from AAVS1-Neo-M2rtTA (Addgene \#60843) with primers containing restriction sites for *SalI* and *ClaI*. After amplification and enzyme-digestion, the CAG-rTetR cassette was cloned in the Puro-Cas9 donor vector (Addgene \#58409). Finally, a gBlock fragment (IDT Technologies) designed with two opposite poly-A sequences was cloned using *MluI* and *ClaI* enzymes. A gRNA sequence targeting the *AAVS1* intron 1 (5′-GGGGCCACTAGGGACAGGAT-3′) was in vitro transcribed (IVT). To edit the iPSCs, 200.000 cells were electroporated with 100 pmol Cas9 nuclease (IDT - Integrated DNA Technologies), 120 pmol the IVT-gRNA against *AAVS1* intron 1, and 5 μg of linearized donor vector. Electroporation was performed using Neon Transfection System (ThermoFisher) at 1400 V, 5 ms and 3 pulses in a 100 μl tip. Cells were then selected with 1 μg/ml puromycin.

Southern blot {#s0040}
-------------

Genomic DNA from each cell line was isolated with Maxwell® RSC Cultured Cells DNA Kit (Promega). 6 μg of DNA from each clone was digested with *SphI* (for 5′ probe) or *BglII* (for 3′ probe) (New England Biolabs), separated on a 1% agarose gel and transferred to a nylon membrane (RPN303B, Amersham). Membranes were hybridized with DIG-dUTP labeled probes. Probes were detected by an AP-conjugated DIG-Antibody (Roche Diagnostics) using CDP-Star (Sigma-Aldrich) as a substrate for chemiluminescence. Probes were synthesized by PCR using the PCR DIG Probe Synthesis Kit (Roche Diagnostics). 5′ probe was generated using plasmidic DNA and 3′ probe using genomic DNA as a templates. Primers used for probes are detailed in [Table 2](#t0010){ref-type="table"}.

T7 endonuclease assay {#s0045}
---------------------

iCas9-FL-BCP-hiPSCs were treated with doxycycline (2 μg/ml) for two days before and during transfection. Cells were dissociated with Accutase (Stem Cell Technologies) and 200.000 cells were electroporated with 120 pmol of a single IVT-gRNA (*MLL*, *GATA2* or *AF4*). Genomic DNA was extracted four days after gRNA transfection. Genomic regions flanking the CRISPR target sites were PCR amplified ([Table 1](#t0005){ref-type="table"}). PCRs were denatured and re-annealed and then PCRs were treated with 5U of T7EI at 37 °C for 1 h.Table 1Summary of quality control testing and results for iCas9-FL-BCP-hiPSC.Table 1ClassificationTestResultDataMorphologyPhotographyhESC-like morphology[Fig. 1](#f0005){ref-type="fig"} panel E topAP stainingPositive[Fig. 1](#f0005){ref-type="fig"} panel E bottomPhenotypeqPCRExpression of pluripotency markers: *OCT4*, *NANOG*, *SOX2*, *CRIPTO*, *REX*, *DNMT3B*[Fig. 1](#f0005){ref-type="fig"} panel FPromoter demethylationloss of CpG methylation in *OCT4* and *NANOG* promoters[Fig. 1](#f0005){ref-type="fig"} panel GFlow cytometrySSEA-3 (76%), SSEA-4 (100%), TRA-1-60 (100%) and TRA-1-81 (99%)[Fig. 1](#f0005){ref-type="fig"} panel HGenotypeKaryotype47 (XX) + 20\
Resolution: 400-band level[Fig. 1](#f0005){ref-type="fig"}S panel CIdentityVDJH (BCR) rearrangementIncomplete VDJH rearrangement (progenitor B cell)[Fig. 1](#f0005){ref-type="fig"}S panel AMutation analysisSouthern blotOne specific insertion at *AAVS1* locus[Fig. 1](#f0005){ref-type="fig"} panel BMicrobiology and virologyMycoplasmaMycoplasma tested by PCR: negative[Fig. 1](#f0005){ref-type="fig"}S panel BDifferentiation potentialTeratoma formationRepresentation of all three germ layers[Fig. 1](#f0005){ref-type="fig"} panel IDonor screeningN/AGenotype additional infoN/A

In vitro transcription {#s0050}
----------------------

T7 RNA polymerase promoter was added to gRNA sequences by PCR using as a template the pSpCas9(BB)-2A-GFP (PX458) plasmid (Addgene \#48138) containing the guide RNA sequences for *MLL*, *GATA2* or *AF4*. PCR amplification were performed using specific forward primers and a universal reverse primer ([Table 2](#t0010){ref-type="table"}). PCR products were used as templates for IVT using the HiScribe™ T7 High Yield RNA Synthesis Kit (New England Biolabs). The resulting gRNAs were purified using the MEGAclear kit (Life Technologies), eluted in RNase-free water and stored at − 80 °C until use.

Mycoplasma test {#s0055}
---------------

Primers used are listed in [Table 2](#t0010){ref-type="table"}. PCR conditions were:94 °C: 20″× 40 cycles94ªC: 20″55 °C: 20″ (Nature primer) or 58 °C: 10″ (M1 primer)65ªC: 20--40″Table 2Antibodies and primers used in this study.Table 2Antibodies used for immunocytochemistry/flow-citometryAntibodyDilutionCompany Cat \# and RRIDSSEA-3-PERat anti-SSEA-31:100BD Bioscience Cat\#560237, RRID:[AB_1645542](nif-antibody:AB_1645542){#ir0005}SSEA-4-v450Mouse anti-SSEA-41:100BD Bioscience Cat\#561156, RRID:[AB_10896140](nif-antibody:AB_10896140){#ir0010}TRA-1-60-BV510Mouse anti-TRA-1-601:100BD Bioscience Cat\#563188, RRID:[AB_2637036](nif-antibody:AB_2637036){#ir0015}TRA-1-81-AlexaFlour647®Mouse anti-TRA-1-811:100BD Bioscience Cat\#560793, RRID:[AB_10550550](nif-antibody:AB_10550550){#ir0020}  PrimersTargetForward/Reverse primer (5′--3′)Genomic PCR5′ junctionCTGCCGTCTCTCTCCTGAGT/GTGGGCTTGTACTCGGTCAT3′ junctionGGCGATCTGACGGTTCACTAAAC/GAATCCACCCAAAAGGCAGCSouthern blot5′ probeAGGTTCCGTCTTCCTCCACT/GTCCAGGCAAAGAAAGCAAG3′ probeACAGGTACCATGTGGGGTTC/CTTGCCTCACCTGGCGATATT7 assay*MLL*CAGCACTCTCTCCAATGGCA/TAAGCCTCCCATCTCCCACA*AF4*GGGGAAAAAAAACATTTCGGCGACATG/CTACCATTTCCCTCATTCCAATTCACTCC*GATA2*CGTGTCGCTGGGATCAAG/TCCCCAAAGAAAGCCAGAAACRNA in vitro transcription*AAVS1* IVTGAAATTAATACGACTCACTATAGGGGGCCACTAGGGACAGGATGTTTTAGAGCTAGAAA/AAAAGCACCGACTCGGTGCC*MLL* IVTGAAATTAATACGACTCACTATAGTTAGCAGGTGGGTTTAGCGCGTTTTAGAGCTAGAAA/AAAAGCACCGACTCGGTGCC*AF4* IVTGAAATTAATACGACTCACTATAGGTCTCATTCCAGCAACACGTGTTTTAGAGCTAGAAA/AAAAGCACCGACTCGGTGCC*GATA2* IVTCATGTAGTTGTGCGCCGTTTTAGAGCTAGA/AAAAGCACCGACTCGGTGCCPluripotency Markers (qPCR)*OCT4*GGGTTTTTGGGATTAAGTTCTTCA/GCCCCCACCCTTTGTGTT*NANOG*ACAACTGGCCGAAGAATAGCA/GGTTCCCAGTCGGGTTCAC*SOX2*CAAAAATGGCCATGCAGGTT/AGTTGGGATCGAACAAAAGCTATT*REX1*CCTGCAGGCGGAAATAGAAC/GCACACATAGCCATCACATAAGG*CRIPTO*CGGAACTGTGAGCACGATGT/GGGCAGCCAGGTGTCATG*DNMT3B*GCTCACAGGGCCCGATACTT/GCAGTCCTGCAGCTCGAGTTTAHousekeeping gene*GAPDH*GCACCGTCAAGGCTGAGAAC/AGGGATCTCGCTCCTGGAAOff-target genomic PCR*RNF4*CAGACCGTGACTCCCGAAA/GTCAGCGGGGAACAAAAACC*RHOT2*TGTTACTGGGCGAGGGTAGG/CTACGGCCGCTACCTGAGTA*FAIM2*AGGCTCGTCCCATCCTTTTG/CACATCCCCATTTGCTCCCT*RPL8*GCAGGCAGTTCTAGAAGCCA/CCTTAGTTATCTGGATTTCCAGAAC*BTNL8*TAGGAGTCTTGGTGGTGTTCAT/ATATCGTGGCACCTGGCTAC*MYBL2*GCAGTCGGAGGAAGTGACAA/CTCCTGGCCCCTCTTAGACTMycoplasma PCRNatureTGCACCATCTGTCACTCTGTTAACCTC/GGGAGCAAACAGGATTAGATACCCTM1ACACCATGGGAGCTGGTAAT/CTTCATCGACTTTCAGACCCAAGGCAT
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